Volume : 09, Issue : 01, January – 2022
Title:
13.FORMULATION, DEVELOPMENT AND EVALUATION OF BI-LAYER TABLET OF ANTI HIV DRUGS
Authors :
Rohit Dangi*, Rahul Sharma, Dr. Jagdish Chandra Rathi
Abstract :
In the last decade, interest in developing a combination of two or more Active Pharmaceutical Ingredients (API) in a single dosage form (bi-layer tablet) has increased in the pharmaceutical industry, promoting patient convenience and compliance. The present research work was envisaged to develop bilayer tablets to improve therapeutic efficacy of anti-HIV/AIDS drugs for the treatment of sexually transmitted diseases. The combination of two anti-HIV/AIDS drugs i.e. abacavir and lamivudine were used for the preparation of bilayer tablets which act HIV/AIDS infections. The formulations comprise of abacavir as immediate release layer formulated using different superdisintegrants and lamivudine as extended-release layer containing HPMC K4, K15. Evaluation of bilayer tablets were performed for the immediate release abacavir layer and sustain release lamivudine layer with optimization of excipients. The immediate release layer of abacavir showed complete release within 90 min and lamivudine release was extended up to 12 hours. The present study revealed that abacavir and lamivudine bilayer tablets were successfully developed for the use against sexually transmitted infections.
Keywords: Bi-layer tablet, Abacavir, Lamivudine, HIV/AIDS, Superdisintegrants, HPMC
Cite This Article:
Please cite this article in press Rohit Dangi et al, Formulation, Development and Evaluation of Bi-Layer Tablet of Anti- HIV Drugs., Indo Am. J. P. Sci, 2022; 09(01).
Number of Downloads : 10
References:
1. PARASHAR, A.; GUPTA, B.P.; BHARDWAJ, A.K.; SARIN, R. Prevalence of RTIs among women of reproductive age group in Shimla city. Indian J. Comm. Med., v.31, n.1, p.15-17, 2006.
2. WORLD HEALTH ORGANIZATION. WHO. Estimation of the incidence and prevalence of sexually transmitted infections. Report of a WHO consultation. Treviso, Italy, 2002.
3. ROBERT, N.A.; STRICK, N.; LI, Y.; LIN, K.; JIANG, S. Design of a ‘‘microbicide’’ for prevention of sexually transmitted diseases using ‘‘inactive’’ pharmaceutical excipients. Biologicals, v.27, n.1, p.11-21, 1999.
4. KIDD, S.E.; WORKOWSKI, K. Sexualy Transmited Diseases. In: BRUNETTE, G.W et al. CDC health information for international travel 2016: the yellow book. New York: Oxford University Press, 2016.
5. STEEN,R.; CHERSICH, M.; GERBASE, A.; NEILSEN, G.; WENDLAND, A.; NDOWA, F.; AKL, E.A.; LO, Y.R.; DE VLAS, S.J. Periodic presumptive treatment of curable sexually transmitted infections among sex workers: a systematic review. AIDS, v.26, n.4, p.437-445, 2012.
6. Arun K Tiwari, Pawan K Porwal. Fixed-dose combination product: current status among regulatory. Res J Pharm Tech 2009;2:433-8.
7. Bangalore, S Shahane, A Parkar. Compliance and fixed-dose combination therapy. Curr Sci Inc 2007;9:184–9.
8. Patel P, Rai JP, Jain DK, Banweer J. Formulation, development and evaluation of cefaclor extended release matrix tablet. Int J Pharm Pharm Sci 2012; 4(4): 355-357.
9. Sharad Prakash Pandey, Mohammed Azaz Khan, Vinod Dhote, Kanika Dhote, Deepak Kumar Jain. Formulation Development of Sustained Release Matrix Tablet Containing Metformin Hydrochloride and Study of Various Factors Affecting Dissolution Rate. Sch Acad J Pharm 2019; 8 (3): 57–73.
10. Gautam SP, Rai JP, Billshaiya U, Jain N, Vikram P, Jain DK. Formulation and evaluation of mouth dissolving tablet of loperamide. Int J Pharm Sci Res. 2013; 4(5): 1782-1788.